natgillin/translations-raw huggingface dataset:
The vial contains 5 g of hydroxocobalamin.
Svaka bočica sadrži 5 g hidroksokobalamina.
The vial contains 500 mg of rituximab (10 mg/mL).
Bočica sadrži 500 mg rituksimaba (10 mg/ml).
The vial contains a white to off-white cake.
Bočica sadrži bijeli do gotovo bijeli komprimat.
The vial contains a white to pale pink powder.
Bočica sadrži prašak bijele do blijedo ružičaste boje.
The vial contains more than the recommended dose of 2 mg aflibercept.
Napunjena štrcaljka sadrži više od preporučene doze od 2 mg aflibercepta.
The vial contains white to pale yellow powder.
Bočica sadrži prašak bijele ili do blijedo žute boje.
The vial contents may be swirled gently and inverted during dissolution.
Sadržaj bočice može se lagano i preokretati tijekom otapanja.
The vial contents may be swirled gently and inverted during dissolution.
Sadržaj bočice može se lagano preokretati tijekom otapanja.
The vial contents should be inspected for particulate matter and discolouration prior to administration.
Bočicu prije primjene treba vizualno pregledati kako bi se utvrdilo sadrži li čestice i je li promijenio boju.
The vial is contained in a transparent blister pack consisting of a tray with a lid.
Bočica se nalazi u prozirnom blister pakiranju koje se sastoji od podloška i poklopca.
The vial is covered with a shrink-wrapped plastic sleeve .
Bočica je prekrivena plastičnom navlakom („shrink-wrapped“).
The vial is for a single examination only.
Bočica je samo za jednokratnu uporabu.
The vial is for single use only.
Bočica je samo za jednokratnu primjenu.
the vial is not damaged and the seal is not broken
da bočica nije oštećena, a zaštitni poklopac nije slomljen
The vial is then shaken vigorously for a few seconds until the lyophilisate is completely dissolved.
Bočica se zatim nekoliko sekundi dobro protrese dok se liofilizat potpuno ne rastopi.
The vial is to be used in conjunction with an appropriate syringe (100 U markings).
Bočica se mora koristiti zajedno s odgovarajućom štrcaljkom (s oznakama za 100 U).
The vial is to be used in conjunction with an appropriate syringe (100 unit markings).
Bočica se mora koristiti zajedno s odgovarajućom štrcaljkom (s oznakama za 100 jedinica).
The vial may contain high pressure due to radiolysis (see section 12).
Bočica može biti pod visokim tlakom zbog radiolize (vidjeti dio 12).
The vial of lyophilised product powder for injection must be reconstituted with the supplied solvent [sodium chloride 9 mg/mL (0.9%) solution] from the pre-filled syringe using the sterile vial adapter reconstitution device.
Bočica s liofiliziranim praškom za injekciju lijeka mora se rekonstituirati s priloženim otapalom [otopina natrijevog klorida od 9 mg/ml (0,9%)] iz napunjene štrcaljke pomoću sterilnog nastavka za bočicu za rekonstituciju.
The vial of Torisel concentrate must first be diluted with 1.8 ml of diluent withdrawn from the supplied vial to achieve a concentration of temsirolimus of 10 mg/ml.
Bočica Torisel koncentrata mora se prvo razrijediti s 1,8 ml otapala izvučenog iz priložene bočice kako bi se dobila koncentracija temsirolimusa od 10 mg/ml.
The vial should be activated using the Vialmix.
Bočica se mora aktivirati korištenjem Vialmixa.
The vial should be allowed to stand undisturbed for one minute to ensure thorough hydration of the dry substance.
Bočicu treba ostaviti da miruje jednu minutu kako bi se osigurala temeljita hidracija suhe tvari.
The vial should be gently swirled until the medicinal product is dissolved.
Bočicu treba nježno vrtjeti sve dok se lijek ne otopi.
The vial should be held upright, shake gently and the aluminium cap and rubber stopper should be removed.
Bočicu treba držati uspravno, lagano protresti i skinuti aluminijski zatvarač i gumeni čep.
The vial should be reconsituted immediately prior to dilution and use.
Bočica se mora rekonstituirati neposredno prije razrjeđivanja i primjene.
The vial should be vented with a sterile syringe needle or a sterile non-siliconised mini-spike before withdrawing the dispersion.
Bočicu treba odzračiti pomoću sterilne igle za štrcaljku ili sterilnog nesilikoniziranog mini šiljka prije izvlačenja disperzije.
The vial should be visually inspected for particulate matter.
Bočicu treba vizualno pregledati kako bi se uočila čestična tvar.
The vial should be well shaken until a slightly opaque white suspension is obtained.
Bočicu treba dobro protresti, tako da se dobije blago zamućena bijela suspenzija.
The vial should be well shaken until a slightly opaque white suspension is obtained.
Bočicu treba dobro protresti, tako da se dobije blago zamućena, bijela suspenzija.
The vial should never be opened and must be kept inside its tungsten shielding.
Bočica se nikada ne smije otvarati i mora se čuvati unutar svoje volframske zaštite.
The vial should not be shaken, but can be rolled between the palms and gently turned upside-down once.
Bočica se ne smije tresti, ali može je se provrtjeti među dlanovima i jednom nježno preokrenuti gore- dolje.
The vial should not be shaken.
Bočicu ne smijete tresti.
The vial should then be shaken vigorously for one minute while keeping the filter and syringe attached.
Bočicu zatim treba snažno tresti jednu minutu držeći filtar i štrcaljku i dalje pričvršćene.
The vial with NexoBrid powder must be shaken vigorously to fragment the NexoBrid powder cake.
Žustro protresite bočicu s praškom NexoBrid kako biste razlomili skrućeni prašak NexoBrid.
The vial with powder is attached to the Raplixa spray device by inverting the device over the upright vial and pushing the vial into place.
Bočica s praškom se pričvrsti na uređaj RaplixaSpray okretanjem uređaja preko uspravne bočice te se bočica gurne da sjedne na svoje mjesto.
The vial, injection needle, filter needle and syringe are for single use only.
Bočica, igla za injekciju, igla s filterom i štrcaljka su samo za jednokratnu primjenu.
The vials are closed with a butyl rubber stopper and sealed with an aluminium cap.
Bočice su zatvorene čepom od butilne gume i zapečaćene aluminijskom kapicom.
The vials are closed with a halogenobutyl rubber stopper and sealed with an aluminium cap.
Bočice su zatvorene s halogenbutil gumenim čepom i zapečaćene aluminijskom kapicom.
The vials are for single use only.
Bočice su isključivo za jednokratnu uporabu.
The vials are packed into a tungsten container for protective shielding.
Bočice su pakirane u volframski spremnik radi zaštite.
The vials should be examined frequently and should not be used if clumps of material are present or if solid white particles stick to the bottom or wall of the vial, giving it a frosted appearance.
Bočice treba često pregledavati i ne smiju se upotrijebiti ako se pojave grudice ili se krute bijele čestice zalijepe na dno ili stijenke bočice te se ona doima zamrznutom.
The vials should be examined frequently and should not be used if clumps of material are present or if solid white particles stick to the bottom or wall of the vial, giving it a frosted appearance.
Bočice treba često pregledavati i ne smiju se upotrijebiti ako se vide nakupine materijala ili su se krute bijele čestice zalijepile na dno ili stijenke bočice te se ona doima zamrznutom.
The vials should be inspected visually for particulate matter and discoloration prior to administration.
Prije primjene bočice, potrebno je provjeriti moguću prisutnost čestica i promjenu boje.
THE VIALS SHOULD NOT BE SHAKEN
BOČICE SE NE SMIJE TRESTI
The vials should not be shaken.
Bočice se ne smiju tresti.
The viral tropism cannot be predicted by treatment history or assessment of stored samples.
Tropizam virusa nije moguće sa sigurnošću odrediti prema podacima o liječenju kao niti analizom ranije pohranjenih uzoraka krvi.
The virologic failure rate in patients treated with emtricitabine/tenofovir disoproxil fumarate + rilpivirine at week 48 and week 96 was 9.5% and 11.5% respectively, and 4.2% and 5.1% in the emtricitabine/tenofovir disoproxil fumarate + efavirenz arm.
Stopa virološkog neuspjeha u pacijenata liječenih emtricitabinom/tenofovirdizoproksilfumaratom + rilpivirinom iznosila je 9,5% u 48. tjednu i 11,5% u 96. tjednu, dok su u skupini liječenoj emtricitabinom/tenofovirdizoproksilfumaratom + efavirenzom odgovarajuće stope iznosile 4,2% odnosno 5,1%.
The virologic failure rate in patients treated with emtricitabine/tenofovir disoproxil fumarate+rilpivirine at Week 48 and Week 96 was 9.5% and 11.5% respectively, and 4.2% and 5.1% in the emtricitabine/tenofovir disoproxil fumarate + efavirenz arm.
Stopa virološkog neuspjeha u bolesnika liječenih s emtricitabinom/tenofovirdizoproksil fumaratom+rilpivirinom u 48. i 96. tjednu iznosila je 9,5% odnosno 11,5%, te 4,2% i 5,1% u skupini koja prima emtricitabin/tenofovirdizoproksilfumarat + efavirenz.
The virological responses of HCV monoinfected patients treated with Pegasys and ribavirin combination therapy in relation to genotype and pre-treatment viral load and in relation to genotype, pre-treatment viral load and rapid virological response at week 4 are summarised in Table 13 and Table 14, respectively.
Virološki odgovori bolesnika zaraženih HCV-om liječenih kombinacijom lijeka Pegasys i ribavirina ovisno o genotipu i količini virusa prije liječenja te ovisno o genotipu, količini virusa prije liječenja i brzom virološkom odgovoru u 4. tjednu sažeti su u tablici 13, odnosno tablici 14.
The virological responses of patients treated with Pegasys monotherapy and with Pegasys and ribavirin combination therapy in relation to genotype and pre-treatment viral load for HIV-HCV co- infected patients are summarised below in Table 20.
U tablici 20 navedeni su virološki odgovori bolesnika koji su istodobno zaraženi HIV-om i HCV-om, liječenih samo lijekom Pegasys te liječenih lijekom Pegasys u kombinaciji s ribavirinom, ovisno o genotipu i količini virusa prije liječenja.
The virus is found in body fluids such as in the vagina, blood, semen, or saliva (spit).
Virus nalazimo u tjelesnim tekućinama poput onih u vagini, krvi, sjemenoj tekućini ili slini (pljuvački).
The viruses in Versican Plus DHPPi are alive but they have been attenuated (weakened) so that they do not cause disease.
Virusi u cjepivu Versican Plus DHPPi su živi, ali su atenuirani (oslabljeni) tako da ne uzrokuju bolest.
The viruses used in Celvapan are grown in mammal cells (‘vero cells’), as opposed to hen’s eggs.
Virusi korišteni u lijeku Celvapan uzgojeni su u stanicama sisavaca („vero stanicama”) umjesto u jajima kokoši.
The viruses used in Fluenz are grown in hens’ eggs.
Virusi korišteni u lijeku Fluenz uzgajaju se u kokošjim jajima.
The viruses used in Fluenz Tetra are grown in hens’ eggs.
Virusi korišteni u Fluenz Tetra uzgajaju se u kokošjim jajima.
The viruses used in Pandemic Influenza Vaccine H5N1 Baxter AG are grown in mammal cells (‘vero cells’), unlike those in some other flu vaccines, which are grown in hen’s eggs.
Virusi korišteni u cjepivu protiv pandemijske influence H5N1 Baxter AG uzgajaju se u stanicama sisavaca („vero stanicama”) za razliku od određenih drugih cjepiva protiv gripe, koji se uzgajaju u kokošjim stanicama.
The viruses used in Vepacel are grown in mammal cells (‘vero cells’), as opposed to hen’s eggs.
Virusi korišteni u cjepivu Vepacel uzgajaju se u stanicama sisavaca („vero stanicama”) umjesto u kokošjim stanicama.
The viruses used to obtain the surface antigen that are included in Optaflu are grown in mammalian cells, unlike those used for other flu vaccines, which are grown in hen’s eggs.
Virusi korišteni kako bi se dobili površinski antigeni koji su uključeni u cjepivo Optaflu uzgajaju se u stanicama sisavaca, za razliku od onih koji se koriste u drugim cjepivima protiv gripe, koji se uzgajaju u kokošjim jajima.
The vision improvement in the DEX700 group was confounded by cataract formation.
Poboljšanje vida u skupini DEX700 bilo je kompromitirano nastankom katarakte.
The vision of patients receiving Lucentis also remained better than the vision of those receiving sham injections in a study in which injections were given less frequently, with injections every month for the first three months and then every three months.
Vid bolesnika koji su primali Lucentis također je ostao bolji od vida onih koji su primali injekcije placeba u ispitivanju u kojem su injekcije davane rjeđe, uz injekcije svaki mjesec tijekom prva tri mjeseca i potom svaka tri mjeseca.
The visual appearance is as follows: Whitish liquid with fine sediment.
Bjelkasta tekućina sa sitnim talogom.
The vitreous haze score gives an indication of inflammation with zero indicating no inflammation.
Rezultat zamućenosti staklovine daje indikaciju upale dok rezultat nula označava da nije bilo upale.
The VKA should be stopped.
Primjena VKA-e se prekida.
The volume (dose) of suspension should be administered orally within 30 minutes of mixing
Volumen (doza) suspenzije mora se primijeniti kroz usta unutar 30 minuta od pripreme (miješanja).
The volume (expressed in mL) of // Palivizumab // to be administered at one-monthly intervals = [patient weight in kg] multiplied by 0.15
Volumen (izražen u ml) palivizumaba koji će se primijeniti u jednomjesečnim intervalima = [težina bolesnika u kg] pomnožena s 0,15.
The volume (in mL) required is calculated based on the body weight (in kg) of the patient: 0.3 x body weight (in kg), e.g. a volume of 18 mL (180 mg) will be necessary for a body weight of 60 kg (0.3 x 60 = 18 mL).
Potrebni volumen (u ml) izračunava se na temelju tjelesne težine (u kg) bolesnika: 0,3 x tjelesna težina (u kg), npr. za tjelesnu težinu od 60 kg bit će potreban volumen od 18 ml (180 mg) (0,3 x 60 = 18 ml).
The volume after mixing 1 vial of suspension (2.5 ml) with 1 vial of emulsion (2.5 ml) corresponds to 10 doses of vaccine (5 ml).
Volumen dobiven miješanjem 1 bočice suspenzije (2,5 ml) i 1 bočice emulzije (2,5 ml) odgovara 10 doza cjepiva (5 ml).
The volume for injection is selected based on the patients' height and weight (Table 1).
Volumen za injekciju se određuje na temelju visine i težine bolesnika (Tablica 1).
The volume for injection is selected based on the patients' height and weight (Table 1).
Volumen za injekciju se određuje na temelju visine i težine bolesnika(Tablica 1).
The volume for injection is selected based on the patients' height and weight.
Volumen za injekciju se određuje na temelju visine i težine bolesnika.
The volume for injection is selected based on the patients' weight (Table 2).
Volumen za injekciju određuje se na temelju bolesnikove tjelesne težine (Tablica 2).
The volume for injection is selected based on the patients' weight.
Volumen za injekciju određuje se na temelju bolesnikove tjelesne težine.
The volume is 0.075 – 2 mL.
Volumen je u rasponu od 0,075 do 2 ml.
The volume is 0.075 – 3.75 mL.
Volumen je u rasponu od 0,075 do 3,75 ml.
The volume of distribution (Vd) for AsIII is large (>400 L) indicating significant distribution into the tissues with negligible protein binding.
Volumen distribucije (Vd) za AsIII je velik (> 400 l) što ukazuje na značajnu raspodjelu u tkiva sa zanemarivim vezivanjem na proteine.
The volume of distribution (Vd) is 1.1 l x kg-1.
Volumen distribucija (Vd) iznosi 1,1 l x kg-1.
The volume of distribution (Vss) is approximately 165 L which is 2.5-fold of body volume indicating extensive extravascular distribution of safinamide.
Volumen distribucije (Vss) je oko 165 l što je 2,5 puta volumen tijela što ukazuje na opsežnu ekstravaskularnu distribuciju lijeka safinamida.
The volume of distribution at steady state (median Vd of 3.0 to 4.1 litres) was not dependent on the administered dose and indicated that infliximab is predominantly distributed within the vascular compartment.
Volumen distribucije u stanju dinamičke ravnoteže (medijan Vd od 3,0 do 4,1 litre) nije ovisio o veličini primijenjene doze i pokazao je da se infliksimab pretežno distribuira unutar vaskularnog odjeljka.
The volume of distribution at steady state adjusted for bioavailability is 0.57 l/kg in patients with Sickle Cell Syndrome (amounting to approximately 72 and 90 l in children and adults, respectively).
Volumen distribucije u stanju dinamičke ravnoteže prilagođen prema bioraspoloživosti iznosi 0,57 l/kg u bolesnika sa sindromom srpastih stanica (i doseže do 72 l kod djece i 90 l kod odraslih).
The volume of distribution at steady state was 8.64.1 l.
Volumen distribucije u stanju dinamičke ravnoteže iznosi 8,6±4,1 l.
The volume of distribution at steady-state (Vss) determined after intravenous administration at 1–2 mg/kg ranged from approximately 4.4 to 7.0 l/kg.
Volumen distribucije u stanju mirovanja (Vss) određen nakon i.v. aplikacije 1-2 mg/kg bio je u granicama od otprilike 4,4 do 7,0 l/kg.
The volume of distribution at steady-state (Vss) determined after intravenous administration was 13.2 l/kg.
Volumen raspodjele u ravnoteži (Vss) utvrđen nakon intravenske primjene bio je 13,2 l/kg.
The volume of distribution at steady-state following intravenous administration is approximately 5.4 l.
Volumen distribucije u stanju dinamičke ravnoteže nakon intravenske primjene paratireoidnog hormona je otprilike 5,4 l.
The volume of distribution cannot be determined because the active substance is minimally absorbed and has no defined systemic pharmacokinetics.
Volumen distribucije ne može se odrediti jer se djelatna tvar minimalno apsorbira i nema definiranu farmakokinetiku.
The volume of distribution in blood is approximately 150ml/kg.
Volumen distribucije u krvi je približno 150 ml/kg.
The volume of distribution is 0.3 l/kg in dogs and 0.09 l/kg in cats.
Volumen distribucije iznosi 0.3 litara / kg kod pasa i 0.09 litara / kg u mačaka.
The volume of distribution is 0.3 l/kg.
Volumen distribucije iznosi
The volume of distribution is high (approximately 1000 litres), indicating extensive distribution.
Volumen distribucije je velik (oko 1000 litara), što ukazuje na široku distribuciju.
The volume of distribution is moderate with Vss being approximately 50 litres.
Volumen distribucije je umjeren, a Vss iznosi oko 50 litara.
The volume of distribution is moderate with Vss being approximately 50 litres.
Volumen distribucije je umjeren, pri čemu Vss iznosi oko 50 litara.
The volume of distribution of dabigatran of 60-70 L exceeded the volume of total body water indicating moderate tissue distribution of dabigatran.
Volumen distribucije dabigatrana od 60 - 70 L prelazi volumen ukupne tjelesne tekućine i ukazuje na umjerenu raspodjelu dabigatrana u tkiva.
The volume of distribution of dabigatran of 60–70 L exceeded the volume of total body water indicating moderate tissue distribution of dabigatran.
Volumen distribucije dabigatrana od 60 - 70 L prelazi volumen ukupne tjelesne tekućine i ukazuje na umjerenu raspodjelu dabigatrana u tkiva.
The volume of distribution of dabigatran of 60–70 L exceeded the volume of total body water indicating moderate tissue distribution of dabigatran.
Volumen distribucije dabigatrana od 60-70 L prelazi volumen ukupne tjelesne tekućine i ukazuje na umjerenu raspodjelu dabigatrana u tkiva.
The volume of distribution of enoxaparin anti-Xa activity is about 5 litres and is close to the blood volume.
Volumen distribucije anti-Xa aktivnosti enoksaparina iznosi oko 5 litara i gotovo je jednaka volumenu krvi.
The volume of distribution of free aflibercept at steady-state is approximately 8 litres.
Volumen distribucije slobodnog aflibercepta u stanju dinamičke ravnoteže iznosi približno 8 litara.
The volume of distribution of ONIVYDE 80 mg/m2 was 2.6 l/m2, which suggests that ONIVYDE is largely confined to vascular fluid.
Volumen distribucije lijeka ONIVYDE 80 mg/m2 bio je 2,6 l/m2, što upućuje na to da je ONIVYDE u velikoj mjeri ograničen na vaskularnu tekućinu.
The volume of distribution of propranolol is approximately 4 L/kg.
Volumen distribucije propranolola iznosi približno 4 L/kg.
The volume of distribution of romiplostim following intravenous administration of romiplostim decreased nonlinearly from 122, 78.8, to 48.2 ml/kg for intravenous doses of 0.3, 1.0 and 10 μg/kg, respectively in healthy subjects.
Volumen distribucije romiplostima nakon intravenske primjene smanjuje se nelinearno sa 122, 78,8 na 48,2 ml/kg za intravenske doze od 0,3, 1,0 i 10 µg/kg u zdravih ljudi.
The volume of distribution was 4.45 L with a range of 2.62 –
Volumen distribucije iznosio je 4,45 l s rasponom
The volume of injected medicinal product and concentration dose range from 100 to 200 mg/mL did not affect the pharmacokinetics of a medicinal administration to healthy volunteers.
aktivnosti u plazmi, iznosi približno 100% Volumen injiciranog lijeka i raspon koncentracije doze od 100 do 200 mg/l nisu imali učinka na farmakokinetiku lijeka u zdravih dragovoljaca.
The volume of Javlor (concentrate) corresponding to the calculated dose of vinflunine should be mixed in a 100 mL bag of sodium chloride 9 mg/mL (0.9%) solution for infusion.
Volumen Javlora (koncentrata) koji odgovara izračunatoj dozi vinflunina treba umiješati u 100-mililitarsku vrećicu otopine natrijeva klorida 9 mg/mL (0,9%) za infuziju.
The volume of Naglazyme is to be slowly added to the sodium chloride 9 mg/ml (0.9%) solution for infusion.
Volumen Naglazyme-a se polako dodaje u 0,9% otopinu natrijeva klorida (9 mg/ml) za infuziju.
The volume of one vial ranges from 0.075 – 3.75 mL solution (corresponding to 3 – 150 GBq at activity reference time).
Volumen otopine u jednoj bočici u rasponu je od 0,075 do 3,75 ml (što odgovara 3 do 150 GBq u vrijeme umjeravanja aktivnosti).
The volume of one vial ranges from 1 to 3 mL solution (corresponding to 925 to 2,770 MBq at calibration time).
Volumen jedne bočice je u rasponu od 1 do 3 ml otopine (što odgovara 925 do 2.770 MBq na kalibracijsko vrijeme).
The volume of reconstituted concentrate corresponding to the calculated individual dose should be further diluted with either sodium chloride 9 mg/ml (0.9 %) solution for injection or 50 mg/ml (5 %) glucose solution for infusion, to a final concentration of between 25 and 50 microgram per ml in the solution for infusion, for example:
Kako bi se dobila konačna koncentracija topotekana između 25 i 50 mikrograma po ml u otopini za infuziju, potrebno je volumen rekonstituiranog koncentrata koji odgovara izračunatoj individualnoj dozi, dodatno razrijediti ili pomoću otopine natrijevog klorida 9 mg/ml (0,9%) za injekciju ili pomoću otopine glukoze 50 mg/ml (5%) za infuziju, npr.:
The volume of reconstituted suspension corresponding to the calculated dose is extracted through the filter provided and further diluted with additional 50 ml sodium chloride 9 mg/ml (0.9 %) solution for injection according to the detailed instructions shown below.
Volumen rekonstituirane suspenzije koji odgovara izračunatoj dozi izvuče se kroz priloženi filtar i dalje razrijedi s dodatnih 50 ml otopine natrijeva klorida 9 mg/ml (0,9 %) za injekciju prema detaljnim uputama u nastavku.
The volume of reconstituted Xiapex to be administered into the plaque is 0.25 ml (for reconstitution instructions, see section 6.6, Table 13).
Volumen rekonstituiranog Xiapexa koji treba primijeniti u plak je 0,25 ml (za upute o rekonstituciji, vidjeti dio 6.6, tablicu 13).
The volume of sodium chloride 9 mg/mL (0.9%) solution for injection or 5% glucose injection should be adjusted so as not to exceed 5 mL/kg of patient weight at any given dose of Empliciti.
Volumen otopine natrijeva klorida 9 mg/ml (0,9%) za injekcije ili otopine glukoze 5% za injekcije treba prilagoditi tako da ni kod jedne primijenjene doze lijeka Empliciti ne premaši vrijednost od 5 ml/kg bolesnikove tjelesne težine.
The volume of sodium chloride 9 mg/mL (0.9%) solution for injection or 5% glucose injection should be adjusted so as not to exceed 5 mL/kg of patient weight at any given dose of Empliciti.
Volumen otopine natrijeva klorida za injekcije 9 mg/ml (0,9%) ili otopine glukoze 5% za injekcije treba prilagoditi tako da ni kod jedne primijenjene doze lijeka Empliciti ne premaši vrijednost od 5 ml/kg bolesnikove tjelesne težine.
The volume of suspension to be withdrawn for dose quantities is calculated as follows:
Volumen suspenzije koji treba izvući za određenu dozu računa se na sljedeći način:
The volume of the Adjupanrix vial after mixing is at least 5 ml.
Volumen cjepiva Adjupanrix u bočici nakon miješanja sadrži najmanje 5 ml.
The volume of the injection should be not less than
Volumen injekcije ne smije biti manji od 1 ml niti veći od